Chemokines News and Research

RSS

Ponatinib identified as a potent inhibitor of SARS-CoV2-induced cytokine storm

Researchers at the Human Biology Division, Fred Hutchinson Cancer Research Center in Washington, United States, found that the FDA-approved, multi-kinase inhibitor Ponatinib is a potent inhibitor of the N-terminal domain (NTD) -mediated cytokine storm. Ponatinib is an oral drug used for the treatment of chronic myeloid leukemia (CML).

14 Apr 2021

Exercise training may slow breast cancer growth by increasing anti-tumor immune response

Exercise training may slow tumor growth and improve outcomes for females with breast cancer - especially those treated with immunotherapy drugs - by stimulating naturally occurring immune mechanisms, researchers at Massachusetts General Hospital and Harvard Medical School have found.

12 Apr 2021

Widely available drug reduces morbidity, mortality in COVID-19-infected mice

Mount Sinai researchers have found that a widely available and inexpensive drug targeting inflammatory genes has reduced morbidity and mortality in mice infected with SARS-CoV-2, the virus that causes COVID-19.

31 Mar 2021

SARS-CoV-2 spike stimulates hyperinflammation via Toll-like receptor 2

A new study, released on the bioRxiv* preprint server, describes the mechanism of inflammation in severe COVID-19, besides revealing a potential new therapeutic target to modulate the severity of COVID-19.

19 Mar 2021

Study characterizes shifting neoantigen burden between primary and metastatic tumors within HNSCC

Oncotarget published "Genomic and neoantigen evolution from primary tumor to first metastases in head and neck squamous cell carcinoma" which reported that prior work has characterized changes in the mutation burden between primary and recurrent tumors; however, little work has characterized the changes in neoantigen evolution.

18 Mar 2021

Study proves that postural orthostatic tachycardia syndrome may be an autoimmune disorder

The symptoms of postural orthostatic tachycardia syndrome, or POTS, can be as varied as they are confounding. There can be fatigue, pain, bleeding disorders and anxiety. Heart palpitations and lightheadedness are common.

16 Mar 2021

Research looks at inflammatory nature of lipid nanoparticle component in mRNA vaccines

In a recent bioRxiv preprint research paper, Botond Z. Igyártó and colleagues from Thomas Jefferson University demonstrated the inflammatory nature of the lipid nanoparticles (LNPs).

15 Mar 2021

SARS-CoV-2 can infect blood monocytes and trigger inflammation, finds study

Researchers found about 10% of blood monocytes in coronavirus disease 2019 (COVID-19) patients are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). These monocytes then die, leading to the release of cytokines – a feature associated with severe and critical COVID-19.

11 Mar 2021

Study clarifies the role of collagen during pancreatic cancer development

Contrary to long-held beliefs, Type I collagen produced by cancer-associated fibroblasts may not promote cancer development but instead plays a protective role in controlling pancreatic cancer progression, reports a new study from researchers at The University of Texas MD Anderson Cancer Center.

4 Mar 2021

SARS-CoV-2 modulates host cell central carbon metabolism for reproduction

A team of scientists from Sweden and India has recently characterized the host cell metabolic alterations associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Their findings reveal that SARS-CoV-2 modulates the host cell's central carbon metabolism to facilitate replication and infection propagation.

28 Feb 2021

SARS-CoV-2 does not infect the entire body in the same way, finds study

COVID-19, the disease caused by the pandemic coronavirus SARS-CoV-2, is primarily regarded as a respiratory infection. Yet the virus has also become known for affecting other parts of the body in ways not as well understood, sometimes with longer-term consequences, such as heart arrhythmia, fatigue and "brain fog."

24 Feb 2021

Study identifies immune profile of people with severe COVID-19

A team of researchers at Georgetown University Medical Center, USA, investigated how SARS-CoV-2 affects the immune system’s response during and after infection and contributes to the severity of COVID-19.

22 Feb 2021

COVID-19 and lung cancer have a common pathway, say researchers

A new preprint on the bioRxiv* server describes the common features COVID-19 shares with lung cancer.

19 Feb 2021

Researchers study host and viral transcriptomes in tandem to shed light on SARS-CoV-2 infection

In a new study, researchers discuss the use of simultaneous sequencing of both human and viral genes to better understand SARS-CoV-2's infection pathway.

15 Feb 2021

Study describes mechanism that limits immunosupressive activity of tumor-associated macrophages

Tumor cells are able to avoid the attack of the immune system through several mechanisms. For instance, these can secrete factors that turn macrophages -cells in the immune system- into dual action agents that contribute to the tumor progress and will protect it from immune body defenses: these become, thus, the tumor-associated macrophages (TAMs).

13 Feb 2021

Could Galectin-3 be a potential biomarker to help identify severe COVID-19 early?

Researchers have measured the galectin-3 levels in the sera of hospitalized patients. They found initial high levels indicate patients will become severely ill, suggesting it could be used as a predictor of severe disease.

10 Feb 2021

Can early use of colchicine reduce COVID-19 mortality?

The COVID-19 pandemic, caused by SARS-CoV-2, has caused well over 2.3 million deaths in a little over a year. A new meta-analysis reports the potential utility of colchicine in treating SARS-CoV-2 infection and forestalling severe and life-threatening inflammation of the lungs and other organs.

8 Feb 2021

Insight into role of aging in response to SARS-CoV-2 infection

Researchers at the University of California, Irvine set out to determine the differences between young people and older adults regarding their host responses against SARS-CoV-2. The team revealed that independent of disease severity, COVID-19 was linked to a significant shift in plasma inflammatory factors. The research is posted to the pre-print server medRxiv*.

3 Feb 2021

Elevated ACE2 and inflammation levels increase risk for pregnant women infected with SARS-CoV-2

Among the hundred million or so cases of coronavirus disease 2019 (COVID-19) that have occurred since the pandemic began, pregnant women have been a conspicuous risk group. However, the exact nature of the risk they and their fetuses face, and the mechanism by which it operates, is far from clear.

2 Feb 2021

SARS-CoV-2 triggers development of new-onset IgG autoantibodies in hospitalized COVID-19 patients

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent for coronavirus disease 2019 (COVID-19), is associated with several clinical features common in autoimmune diseases as myalgias, arthralgias, fatigue, and rashes. COVID-19 patients also exhibit less common autoimmunity manifestations such as myositis, thrombosis, myocarditis, encephalitis, vasculitis, and arthritis.

1 Feb 2021